Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...154155156157158159160161162163164...10651066»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan. (Pubmed Central) -  Jun 8, 2023   
    The maximum proportion of cases prescribed with dexamethasone increased remarkably from 2.5 to 35.2% in the study population before and after week 29 (July 2020), when dexamethasone was included in the guidance...We showed the trends of steroid prescriptions in COVID-19 inpatients. The results showed that guidance can influence drug treatment provided during an emerging infectious disease pandemic.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Rice florigens control a common set of genes at the shoot apical meristem including the F-BOX BROADER TILLER ANGLE 1 that regulates tiller angle and spikelet development. (Pubmed Central) -  Jun 7, 2023   
    We uncoupled the contribution of Hd3a and RFT1 to transcriptome reprogramming at the SAM by RNA-sequencing of dexamethasone-inducible over-expressors of single florigens and wild type plants exposed to photoperiodic induction...Detailed functional studies on some candidates revealed a role for LOC_Os04g13150 in determining tiller angle and spikelet development and the gene was renamed BROADER TILLER ANGLE 1 (BRT1). We identified a core set of genes controlled by florigen-mediated photoperiodic induction and defined the function of a novel florigen target controlling tiller angle and spikelet development.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Effects of combined cannabidiol (CBD) and hops (Humulus lupulus) terpene extract treatment on RAW 264.7 macrophage viability and inflammatory markers. (Pubmed Central) -  Jun 7, 2023   
    The combination of CBD and Hops 1 showed effects in LPS-stimulated RAW 264.7 cells superior to the single substance treatments and akin to the control hydrocortisone...The anti-inflammatory effect of CBD and its cellular uptake positively correlated with terpene concentration, as indicated by comparison with a hemp extract containing both CBD and terpenes. These findings may contribute to the postulations for the so-called "entourage effect" between cannabinoids and terpenes and support the potential of CBD combined with phytomolecules from a non-cannabinoid source, such as hops, for the treatment of inflammatory diseases.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    Review, Journal:  Commonly prescribed medications associated with alopecia. (Pubmed Central) -  Jun 7, 2023   
    Few studies with high levels of evidence have been conducted on the topic of medication-associated alopecia. The mechanisms of hair loss must be further identified to provide effective management.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Access and safety of dexamethasone in multiple myeloma patients (Pubmed Central) -  Jun 7, 2023   
    Neutralization of histone using STC3141, especially at high dose, had similar therapeutic effects to dexamethasone in this LPS double-hit rat ALI model, with significantly decreased circulating histone concentration, improved acute lung injury and oxygenation. No abstract available
  • ||||||||||  Agamree (vamorolone) / Santhera
    Trial primary completion date:  A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) (clinicaltrials.gov) -  Jun 7, 2023   
    P2,  N=39, Recruiting, 
    No abstract available Trial primary completion date: Aug 2024 --> Jan 2025
  • ||||||||||  Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Rituxan (rituximab) / Roche
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) -  Jun 7, 2023   
    P2,  N=24, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Aug 2027 --> Feb 2028 | Initiation date: Dec 2022 --> May 2023 | Trial primary completion date: Aug 2025 --> Feb 2026
  • ||||||||||  prednisone / Generic mfg., dexamethasone injection / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  Intratympanic Steroid for Bell's Palsy (clinicaltrials.gov) -  Jun 7, 2023   
    P2/3,  N=11, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=90 --> 11 | Trial completion date: Dec 2022 --> Jun 2023
  • ||||||||||  itacitinib (INCB039110) / Incyte
    Trial completion date, Trial primary completion date:  GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) -  Jun 6, 2023   
    P2/3,  N=155, Active, not recruiting, 
    This study proved the significant efficacy of short-course 0.137 mg/mL betamethasone mouthwash therapy for treating erosion and pain, providing a novel topical agent for patients with severe EOLP. Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
    Enrollment open, Trial initiation date, EGFR exon 20, Metastases:  Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (clinicaltrials.gov) -  Jun 6, 2023   
    P2,  N=54, Recruiting, 
    N=32 --> 1 | Trial completion date: Jan 2024 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> May 2023; Difficulties getting subjects recruited and enrolled. Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Jun 2023
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, dexamethasone / Generic mfg.
    Journal, IO biomarker:  Dexamethasone enhances venetoclax-induced apoptosis in acute myeloid leukemia cells. (Pubmed Central) -  Jun 5, 2023   
    This may lead to a diminished protective effect of BM-MSCs on AML cells. Together, our findings indicated that venetoclax in combination with dexamethasone could be a promising therapy in AML.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal:  Effect of Preoperative Dexamethasone on Postoperative Pain in Patients Undergoing Tonsillectomy. (Pubmed Central) -  Jun 5, 2023   
    There was a noteworthy decreased mean pain score postoperatively of Group A on the first, third, and fifth day. (p-value = < 0.001).The results of this study suggest that a single preoperative injection of dexamethasone for patients undergoing tonsillectomy by cold dissection method significantly reduced postoperative pain.
  • ||||||||||  hydrocortisone / Generic mfg.
    Clinical, Journal:  What a difference timing makes: Cortisol effects on neural underpinnings of emotion regulation. (Pubmed Central) -  Jun 5, 2023   
    (p-value = < 0.001).The results of this study suggest that a single preoperative injection of dexamethasone for patients undergoing tonsillectomy by cold dissection method significantly reduced postoperative pain. In this randomized, double-blind, placebo-controlled neuroimaging experiment, 105 participants (54 men, 51 women) received 20
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Anti-inflammatory compounds reduce equine herpesvirus type 1 replication and cell-to-cell spread. (Pubmed Central) -  Jun 5, 2023   
    We show that the NSAID, flunixin meglumine (FM), and the JAK/STAT inhibitor, AG490, significantly reduced virus yields in endothelial and epithelial cell lines, and this inhibition was similar for two neurologic and two non-neurologic EHV-1 strains. In addition to reducing virus yields, AG490 and FM also significantly reduced the ability of EHV-1 to spread laterally from cell to cell.
  • ||||||||||  Cortone (cortisone acetate) / Merck (MSD)
    Preclinical, Journal:  Age-associated features of norovirus infection analysed in mice. (Pubmed Central) -  Jun 5, 2023   
    Interestingly, viral uptake depended on passive ileal absorption of luminal virus, a process blocked by cortisone acetate administration, which prevented ileal viral RNA accumulation...Together, our findings reveal developmentally associated aspects of persistent MNoV infection, including distinct tissue and cellular tropism, mechanisms of interferon regulation and severity of infection in the absence of interferon signalling. These emphasize the importance of defining viral pathogenesis phenotypes across the developmental spectrum and highlight passive viral uptake as an important contributor to enteric infections in early life.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Mifeprex (mifepristone) / Danco Laboratories
    Journal:  FKBP5 blockade may provide a new horizon for the treatment of stress-associated disorders; an in-silico study. (Pubmed Central) -  Jun 5, 2023   
    The developed films hold great promise for potentially treating RAS and other oral conditions. While the current in-silico repurposing study could identify potential drugs (that are already approved and are widely available) for designing clinical trials in patients with stress-associated disorders (eg, FS), any future clinical trial should consider the pharmacological profile of the desired drug and also the characteristics and comorbidities of the patients in order to foster a success.
  • ||||||||||  Review, Journal:  Therapeutic strategies for COVID-19: progress and lessons learned. (Pubmed Central) -  Jun 5, 2023   
    Here, we summarize progress with COVID-19 drug discovery, based on accumulated findings since the pandemic began and a comprehensive list of clinical and preclinical inhibitors with anti-coronavirus activities. We also discuss the lessons learned from COVID-19 and other infectious diseases with regard to drug repurposing strategies, pan-coronavirus drug targets, in vitro assays and animal models, and platform trial design for the development of therapeutics to tackle COVID-19, long COVID and pathogenic coronaviruses in future outbreaks.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Journal, Surgery, Bariatric surgery:  Impact of Emend on Perioperative Bariatric Surgery Antiemetic Utilization, Patient Satisfaction, and Costs. (Pubmed Central) -  Jun 5, 2023   
    We also discuss the lessons learned from COVID-19 and other infectious diseases with regard to drug repurposing strategies, pan-coronavirus drug targets, in vitro assays and animal models, and platform trial design for the development of therapeutics to tackle COVID-19, long COVID and pathogenic coronaviruses in future outbreaks. Fosaprepitant is a relevant alternative in preventing and treating PONV in patients who underwent bariatric/metabolic surgical procedures.
  • ||||||||||  dexamethasone / Generic mfg., everolimus / Generic mfg.
    Journal:  Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). (Pubmed Central) -  Jun 5, 2023   
    There were no significant differences between groups seen in either of the coprimary endpoints; furthermore, we found no association between whole blood everolimus trough concentrations and toxicity. Although limited by poor enrollment, the results of this study do not suggest that prophylactic dexamethasone mouthwash is superior to therapeutic dexamethasone mouthwash (initiated at the first sign of mouth pain) for reducing the incidence or severity of mIAS from everolimus.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Neurocognitive outcomes at age 5?years after prophylactic hydrocortisone in infants born extremely preterm. (Pubmed Central) -  Jun 5, 2023   
    P3
    Although limited by poor enrollment, the results of this study do not suggest that prophylactic dexamethasone mouthwash is superior to therapeutic dexamethasone mouthwash (initiated at the first sign of mouth pain) for reducing the incidence or severity of mIAS from everolimus. This exploratory analysis provides reassuring data regarding the long-term neurodevelopmental safety of prophylactic hydrocortisone in infants born extremely preterm.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Immuno-oncology:  AHOD2131: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (clinicaltrials.gov) -  Jun 5, 2023   
    P3,  N=1875, Recruiting, 
    This exploratory analysis provides reassuring data regarding the long-term neurodevelopmental safety of prophylactic hydrocortisone in infants born extremely preterm. Trial completion date: Jun 2030 --> Apr 2031 | Trial primary completion date: Jun 2030 --> Apr 2031